newlimit

Longevity technology startup NewLimit, co-founded by Coinbase founder Brian Armstrong, announced the completion of a $435 million Series C funding round, with a valuation of $3.1 billion. This round was led by Founders Fund, a fund under Peter Thiel, with continued participation from Abstract Ventures, Kleiner Perkins, NFDG, Eli Lilly Ventures, Valor Equity Partners, and new investors including Thrive Capital, Greenoaks, and Quiet Capital.In 2021, Brian Armstrong, along with former GV partner and bioengineer Blake Byers and stem cell biologist Jacob Kimmel, jointly invested $110 million to establish NewLimit in South San Francisco.

ChainCatcher news, Coinbase CEO co-founded longevity research company NewLimit forwarded a message from its co-founder Jacob Kimmel stating that NewLimit has recently secured an additional $45 million in funding, with investors including Lilly Ventures, Duke University, S32, Abstract, and participation from existing shareholders such as Kleiner Perkins, Dimension, Human Capital, and Boost VC.This round of financing is based on technological breakthroughs in its young liver function restoration project, with plans to initiate clinical research in the coming years.

ChainCatcher news, according to TechCrunch, NewLimit, co-founded by Coinbase CEO Brian Armstrong, has completed a $130 million Series B funding round, led by Kleiner Perkins, with participation from Nat Friedman, Daniel Gross, Khosla Ventures, Founders Fund, Dimension Capital, Elad Gil, Garry Tan, Patrick Collison, and others.It is reported that the company mainly develops anti-aging therapies using artificial intelligence models and has currently identified three prototype drugs that can reprogram liver cells.